North Chicago, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells healthcare products. Valued at $232.4 billion by market cap, ABT is a global leader in the large and growing in-vitro diagnostic market, and its products include pharmaceuticals, nutritional, diagnostics, and vascular products. The medical device manufacturer is expected to announce its fiscal third-quarter earnings for 2025 before the market opens on Wednesday, Oct. 15.

Ahead of the event, analysts expect ABT to report a profit of $1.30 per share on a diluted basis, up 7.4% from $1.21 per share in the year-ago quarter. The company has beat or matched Wall Street’s EPS estimates in its last four quarterly reports.

Why Investors Are Excited About Palantir Stock Again

Government Shutdown, Job Report and Other Key Things to Watch this Week

PayPal Could Still Be 20% Too Cheap - Use Options to Play PYPL

Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.

For the full year, analysts expect ABT to report EPS of $5.15, up 10.3% from $4.67 in fiscal 2024. Its EPS is expected to rise 10.3% year-over-year to $5.68 in fiscal 2026.

ABT stock has outperformed the S&P 500 Index’s ($SPX) 15.6% gains over the past 52 weeks, with shares up 18.5% during this period. Similarly, it considerably outperformed the Health Care Select Sector SPDR Fund’s (XLV) 11.5% dip over the same time frame.

On Jul. 17, Abbott released its Q2 results, reporting a 7.4% year-over-year revenue growth to $11.1 billion, slightly exceeding consensus estimates. The company's adjusted EPS of $1.26 increased 10.5% from the same quarter last year, beating analyst expectations by a penny. Despite the better-than-expected performance, ABT's shares dropped 8.5% following the earnings release.

Analysts’ consensus opinion on ABT stock is bullish, with a “Strong Buy” rating overall. Out of 27 analysts covering the stock, 19 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” and six give a “Hold.” ABT’s average analyst price target is $144.48, indicating a potential upside of 8.2% from the current levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com